Madrigal Pharmaceuticals, Inc. a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), announced multiple resmetirom data presentations at the upcoming American Association… read more.
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA)… read more.
Rehab Elhiny (University College, Cork, Ireland and Minia University, Egypt) was awarded the best poster prize for her poster entitled ‘Goal attainment, medication adherence and guideline adherence in… read more.
Therapeutic advances in lung cancer Molecular testing before the start of treatment is good clinical practice (GCP) and confers considerable benefits in survival, according to Professor Joanna Chorostowska-Wynimko… read more.
Plus Therapeutics a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the… read more.
“Drug wastage jeopardises sustainability” was one of the driving concepts behind the ROAD (Re-dispensing unused oral anticancer drugs) project, according to Dr Charlotte Bekker (Radboud University Medical Centre)…. read more.
UCB announced that the results of its double-blind TOGETHER (AH0003) Phase IIa study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild… read more.
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 11 presentations offering insights into the research and development… read more.
DURECT Corporation a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce… read more.
Gilead Sciences, Inc. announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31… read more.
Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of… read more.
Alexion, AstraZeneca Rare Disease, will present data from its leading generalised myasthenia gravis (gMG) portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
